[{"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-001", "question": "A 68-year-old man with a history of severe COPD (FEV1 35% predicted) and chronic hypercapnia (baseline PaCO2 55 mmHg) presents with acute-on-chronic hypercapnic respiratory failure requiring non-invasive ventilation. After 48 hours of improvement, his arterial blood gas shows pH 7.36, PaCO2 48 mmHg, PaO2 85 mmHg on 2 L/min nasal cannula. He is alert and comfortable. The next most appropriate step in management is:", "options": ["Gradually wean and discontinue supplemental oxygen to target a PaO2 of 55-60 mmHg", "Continue current oxygen therapy and plan for discharge home with home oxygen", "Increase oxygen flow to achieve a PaO2 > 88 mmHg", "Obtain a venous blood gas to confirm the arterial values", "Initiate acetazolamide 250 mg twice daily to accelerate renal compensation"], "answer": "A", "answer_index": 0, "explanation": "In patients with chronic hypercapnia, the hypoxic drive is a primary respiratory stimulus. Over-oxygenation can suppress this drive, leading to worsening hypercapnia and acidosis. The target PaO2 is 55-60 mmHg or SpO2 88-92%, which provides adequate oxygenation while minimizing the risk of CO2 retention. Increasing oxygen (C) is dangerous, and acetazolamide (E) is not indicated in acute-on-chronic respiratory failure as it can worsen acidosis by inhibiting compensatory metabolic alkalosis.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nPatient Profile:\n- 68-year-old man with severe COPD (FEV1 35% predicted)\n- Chronic hypercapnia (baseline PaCO2 55 mmHg)\n- Presented with acute-on-chronic hypercapnic respiratory failure\n- After 48 hours of NIV, showing improvement\n\nCurrent ABG:\n- pH 7.36 (normal range)\n- PaCO2 48 mmHg (actually below his baseline of 55 mmHg)\n- PaO2 85 mmHg on 2 L/min O2\n- Patient is alert and comfortable\n\nAnalysis of Options:\n\nOption A: Weaning oxygen to target PaO2 55-60 mmHg would be unnecessarily aggressive. His current PaO2 of 85 mmHg is appropriate, and targeting such low values isn't standard practice even in COPD patients.\n\nOption B: This patient has improved significantly - his pH is normal, PaCO2 is actually better than his baseline, and he's comfortable on low-flow oxygen. Planning for discharge with home oxygen assessment is reasonable. However, we need to consider if he meets criteria for long-term oxygen therapy (LTOT).\n\nOption C: Increasing oxygen to achieve PaO2 >88 mmHg is unnecessary. His current PaO2 of 85 mmHg is adequate, and excessive oxygen in COPD patients with chronic hypercapnia can suppress respiratory drive.\n\nOption D: There's no clinical indication to confirm arterial values with venous blood gas. The ABG results are consistent with clinical improvement.\n\nOption E: Acetazolamide is sometimes used for metabolic alkalosis or to stimulate ventilation, but this patient's pH is 7.36 (normal) and his PaCO2 is actually lower than baseline. There's no indication for acetazolamide here.\n\nKey Consideration:\nThe patient has recovered well from his acute exacerbation. His PaCO2 of 48 mmHg is below his chronic baseline of 55 mmHg, suggesting he may have been \"over-ventilated\" or is doing better than usual. The appropriate next step is to continue current management and plan for discharge with appropriate home oxygen if he qualifies based on resting hypoxemia criteria.\n\nThe answer is (B)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-002", "question": "A 45-year-old woman with a history of recurrent calcium oxalate kidney stones presents with acute pancreatitis. Lipase is 1200 U/L, calcium 11.8 mg/dL, PTH 85 pg/mL (normal 10-65). She is not on lithium or thiazides. A pancreatic protocol CT shows diffuse gland enlargement but no necrosis or ductal dilation. The most likely underlying etiology of her pancreatitis is:", "options": ["Primary hyperparathyroidism due to parathyroid adenoma", "Autoimmune pancreatitis (IgG4-related disease)", "Hereditary pancreatitis due to PRSS1 mutation", "Hypertriglyceridemia-induced pancreatitis", "Pancreatitis secondary to a gastrinoma (Zollinger-Ellison syndrome)"], "answer": "A", "answer_index": 0, "explanation": "The triad of hypercalcemia, elevated PTH, and recurrent calcium oxalate stones is classic for primary hyperparathyroidism. Hypercalcemia is a known, though uncommon, cause of pancreatitis. The elevated PTH confirms primary hyperparathyroidism, not secondary causes. While hypertriglyceridemia (D) can cause pancreatitis, it doesn't explain the hypercalcemia and elevated PTH. Gastrinoma (E) is associated with ulcers and diarrhea, not typically hypercalcemia and stones.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nKey findings:\n- 45-year-old woman\n- Recurrent calcium oxalate kidney stones\n- Acute pancreatitis (lipase 1200 U/L)\n- Hypercalcemia: calcium 11.8 mg/dL (elevated)\n- PTH 85 pg/mL (elevated, normal 10-65)\n- Not on lithium or thiazides\n- CT shows diffuse gland enlargement, no necrosis or ductal dilation\n\nThe combination of:\n1. Hypercalcemia (11.8 mg/dL)\n2. Elevated PTH (85 pg/mL)\n3. Recurrent calcium oxalate kidney stones\n\nThis classic triad points to primary hyperparathyroidism. The elevated PTH in the setting of hypercalcemia indicates inappropriate PTH secretion (in secondary hyperparathyroidism, calcium would be low/normal).\n\nPrimary hyperparathyroidism is a known cause of acute pancreatitis. The mechanism involves hypercalcemia leading to:\n- Premature activation of trypsinogen to trypsin within the pancreas\n- Calcium deposition in pancreatic ducts\n- Direct toxic effects on pancreatic acinar cells\n\nThe most common cause of primary hyperparathyroidism (80-85% of cases) is a parathyroid adenoma.\n\nLet me rule out other options:\n- B. Autoimmune pancreatitis: Would expect elevated IgG4, and doesn't explain the hypercalcemia/elevated PTH\n- C. Hereditary pancreatitis: Typically presents earlier in life, doesn't explain the calcium/PTH abnormalities\n- D. Hypertriglyceridemia: No mention of elevated triglycerides, and doesn't explain calcium/PTH findings\n- E. Gastrinoma: Would cause peptic ulcers and diarrhea, not hypercalcemia with elevated PTH (unless part of MEN1, but primary hyperparathyroidism would still be the cause of pancreatitis)\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-003", "question": "A 32-year-old woman presents with 3 weeks of progressive dyspnea and fatigue. Echocardiogram shows a large pericardial effusion with diastolic right atrial and right ventricular collapse. Right heart catheterization reveals equalization of diastolic pressures (RA 18, RV 18, PA 18/20, PCWP 18 mmHg). After pericardiocentesis of 800 mL of serosanguinous fluid, hemodynamics improve. Cytology is negative. Two days later, she develops recurrent dyspnea. Repeat echo shows reaccumulation of the effusion. The most appropriate definitive management is:", "options": ["Repeat pericardiocentesis and initiate colchicine", "Surgical creation of a pericardial window via subxiphoid approach", "Initiation of high-dose prednisone for suspected autoimmune pericarditis", "Pericardiectomy via left thoracotomy", "Intrapericardial instillation of bleomycin"], "answer": "B", "answer_index": 1, "explanation": "Recurrent symptomatic pericardial effusion with tamponade physiology, especially when cytology is negative (ruling out malignancy requiring specific therapy), is a clear indication for a definitive surgical procedure to prevent reaccumulation. A surgical pericardial window (subxiphoid or video-assisted) allows for drainage and biopsy. Pericardiectomy (D) is reserved for constrictive pericarditis. Steroids (C) are for inflammatory causes but are not definitive for recurrent effusion. Intrapericardial chemotherapy (E) is for malignant effusions.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nClinical Presentation:\n- 32-year-old woman with progressive dyspnea and fatigue\n- Large pericardial effusion with cardiac tamponade physiology (diastolic collapse of RA and RV)\n- Equalization of diastolic pressures (classic for tamponade/constrictive physiology)\n- Serosanguinous fluid (800 mL) - cytology negative\n- Rapid reaccumulation within 2 days\n\nKey Considerations:\n\nThe rapid reaccumulation of a large serosanguinous effusion despite negative cytology is concerning. The differential includes:\n- Malignancy (even with negative initial cytology)\n- Idiopathic/viral pericarditis\n- Autoimmune conditions\n- Tuberculosis\n- Uremia\n\nEvaluating Options:\n\nA. Repeat pericardiocentesis and colchicine - Colchicine is useful for recurrent pericarditis, but given rapid reaccumulation of a large effusion, repeated pericardiocentesis alone is not definitive management.\n\nB. Surgical pericardial window (subxiphoid approach) - This provides continuous drainage, allows tissue biopsy for diagnosis, and prevents reaccumulation. It's the standard approach for recurrent effusions, especially when etiology is unclear and rapid reaccumulation occurs.\n\nC. High-dose prednisone - Starting empiric steroids without a diagnosis could mask underlying malignancy or infection (TB). Not appropriate as first-line definitive management.\n\nD. Pericardiectomy via left thoracotomy - This is more invasive and typically reserved for constrictive pericarditis, not primarily for effusions.\n\nE. Intrapericardial bleomycin - This is used for confirmed malignant effusions. Cytology is negative, so this would be premature.\n\nBest Answer:\nGiven the rapid reaccumulation of a large serosanguinous effusion, the most appropriate definitive management is creating a pericardial window. This allows:\n1. Continuous drainage to prevent reaccumulation\n2. Tissue sampling for definitive diagnosis\n3. Relatively low morbidity compared to pericardiectomy\n\nThe subxiphoid approach is preferred as it's less invasive than thoracotomy.\n\nThe answer is (B)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-004", "question": "A 70-year-old man with atrial fibrillation on apixaban (non-valvular) presents with acute onset of right-sided weakness and aphasia 4 hours after symptom onset. NIHSS is 15. CT head shows no hemorrhage. He is not a candidate for IV tPA due to anticoagulation. CT angiography shows a left M1 MCA occlusion. The most appropriate acute intervention is:", "options": ["Administer IV tPA after checking an INR and anti-Xa level", "Proceed directly to mechanical thrombectomy without thrombolysis", "Administer IV protamine to reverse apixaban, then give IV tPA", "Administer andexanet alfa, then give IV tPA", "Initiate IV heparin drip and observe for neurological improvement"], "answer": "B", "answer_index": 1, "explanation": "For patients with acute ischemic stroke and large vessel occlusion (LVO) who are not candidates for IV tPA, mechanical thrombectomy is the standard of care if performed within 24 hours of last known well and meeting other criteria (like NIHSS â‰¥6). Direct thrombectomy is non-inferior to bridging therapy (tPA + thrombectomy). Reversing anticoagulation to give tPA (C, D) delays definitive therapy and adds bleeding risk. Giving tPA on top of therapeutic anticoagulation (A) is contraindicated.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nPatient presentation:\n- 70-year-old man with atrial fibrillation on apixaban\n- Acute right-sided weakness and aphasia (4 hours from onset)\n- NIHSS 15 (moderate-severe stroke)\n- CT head: no hemorrhage\n- CTA: Left M1 MCA occlusion\n- Not a candidate for IV tPA due to anticoagulation\n\nKey considerations:\n\n1. IV tPA contraindication: The patient is on apixaban (a direct factor Xa inhibitor). IV tPA is contraindicated in patients on direct oral anticoagulants (DOACs) unless the drug level is known to be negligible or the last dose was >48 hours ago with normal renal function.\n\n2. Time window: At 4 hours from symptom onset, the patient is within the mechanical thrombectomy window (up to 24 hours in select patients, standard window up to 6 hours for anterior circulation).\n\n3. Large vessel occlusion (LVO): M1 MCA occlusion is a classic indication for mechanical thrombectomy.\n\nAnalyzing options:\n\n- A: Checking anti-Xa level could be considered, but even with reversal, giving tPA after DOAC exposure carries significant bleeding risk. This delays treatment.\n\n- B: Mechanical thrombectomy is the standard of care for LVO strokes. It can be performed regardless of anticoagulation status and doesn't require thrombolysis. Multiple trials (MR CLEAN, SWIFT PRIME, EXTEND-IA, etc.) support thrombectomy for M1 occlusions.\n\n- C: Protamine reverses heparin, NOT apixaban. This is incorrect.\n\n- D: Andexanet alfa reverses factor Xa inhibitors, but giving tPA after reversal is not standard practice and carries uncertain bleeding risk. The reversal-then-tPA approach is not established.\n\n- E: IV heparin would increase bleeding risk and is not appropriate acute stroke management.\n\nBest answer: Mechanical thrombectomy is indicated for this patient with a large vessel occlusion, moderate-severe deficit (NIHSS 15), within the time window, and can be performed safely regardless of anticoagulation status.\n\nThe answer is (B)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-005", "question": "A 55-year-old man with alcoholic cirrhosis (Child-Pugh B) is admitted with hepatic encephalopathy. He is started on lactulose. On day 3, he develops acute kidney injury. Serum sodium is 122 mEq/L (down from 128 on admission), creatinine 2.4 mg/dL (baseline 0.9), and he is clinically envolemic. Urine sodium is <10 mEq/L, urine osmolality 550 mOsm/kg. The most likely cause of his hyponatremia is:", "options": ["Syndrome of inappropriate antidiuretic hormone secretion (SIADH)", "Acute tubular necrosis from sepsis", "Hepatorenal syndrome type 1", "Pseudohyponatremia from hypertriglyceridemia", "Hyponatremia due to lactulose-induced diarrhea"], "answer": "E", "answer_index": 4, "explanation": "Lactulose causes an osmotic diarrhea, leading to loss of sodium and water, but relatively more water loss, resulting in hypertonic hyponatremia. The clinical picture (envolemic, high urine osmolality, low urine sodium) is consistent with volume depletion from GI losses, not SIADH (which has inappropriately high urine sodium). Hepatorenal syndrome (C) is characterized by low urine sodium but typically occurs in the setting of avid sodium retention and ascites, not acute diarrhea. ATN (B) would have high urine sodium.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "Let me analyze this case systematically.\n\nPatient Profile:\n- 55-year-old man with alcoholic cirrhosis (Child-Pugh B)\n- Admitted with hepatic encephalopathy\n- Started on lactulose\n- Day 3: develops AKI\n\nLab Findings:\n- Serum sodium: 122 mEq/L (down from 128) - worsening hyponatremia\n- Creatinine: 2.4 mg/dL (baseline 0.9) - AKI\n- Clinically euvolemic\n- Urine sodium: <10 mEq/L (very low)\n- Urine osmolality: 550 mOsm/kg (concentrated urine)\n\nAnalysis of Options:\n\nA. SIADH: Would show urine sodium >20-40 mEq/L (typically >30), and urine osmolality >100. The low urine sodium (<10) argues strongly against SIADH.\n\nB. ATN from sepsis: ATN typically shows urine sodium >20 mEq/L due to tubular damage and inability to reabsorb sodium. The low urine sodium argues against this.\n\nC. Hepatorenal Syndrome Type 1: This fits well. HRS occurs in cirrhotic patients, characterized by:\n- Functional renal failure\n- Very low urine sodium (<10 mEq/L) - kidneys avidly retain sodium\n- Concentrated urine (high osmolality)\n- Often precipitated by infections, GI bleeding, or large volume paracentesis\n- The patient appears \"euvolemic\" clinically but has effective arterial underfilling due to splanchnic vasodilation\n\nD. Pseudohyponatremia: Would require evidence of hypertriglyceridemia or hyperproteinemia. No indication of this in the case.\n\nE. Lactulose-induced diarrhea: While lactulose can cause diarrhea and volume depletion, this would typically cause hypernatremia (losing hypotonic fluid) or the patient would appear hypovolemic. The concentrated urine and low urine sodium could fit volume depletion, but the patient is described as \"clinically euvolemic.\"\n\nKey Distinction: In cirrhosis, patients can appear euvolemic but have effective hypovolemia due to splanchnic vasodilation. The combination of:\n- Cirrhosis with hepatic encephalopathy\n- AKI with very low urine sodium\n- Concentrated urine\n- Hyponatremia\n\nThis constellation is classic for Hepatorenal Syndrome, where the kidneys respond to perceived hypovolemia by retaining sodium and water, leading to dilutional hyponatremia.\n\nThe answer is (C)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-006", "question": "A 28-year-old pregnant woman at 32 weeks gestation is admitted for severe preeclampsia with BP 170/110 mmHg. She is started on IV magnesium sulfate for seizure prophylaxis and IV labetalol for blood pressure control. One hour after initiation of magnesium, she becomes somnolent, with loss of deep tendon reflexes. Respiratory rate is 8 breaths/min. Serum magnesium level is 9.2 mg/dL. After securing the airway, the most specific immediate treatment is:", "options": ["IV administration of 10% calcium gluconate 1 gram over 10 minutes", "IV administration of furosemide 40 mg to enhance renal excretion", "Immediate hemodialysis", "Discontinuation of magnesium sulfate and administration of IV levothyroxine", "IV administration of pyridostigmine 2 mg"], "answer": "A", "answer_index": 0, "explanation": "Calcium gluconate is the direct antagonist to the life-threatening cardiac and neuromuscular effects of hypermagnesemia. It stabilizes cardiac membranes and reverses respiratory depression caused by magnesium. Furosemide (B) promotes excretion but is not immediate. Dialysis (C) is for severe cases with renal failure but is not the first step after airway management. Pyridostigmine (E) is for myasthenia, not magnesium toxicity.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case of magnesium toxicity in a pregnant woman with preeclampsia.\n\nThe patient has classic signs of magnesium toxicity:\n- Somnolence (CNS depression)\n- Loss of deep tendon reflexes (occurs at Mg levels 9-12 mg/dL)\n- Respiratory depression (RR 8/min)\n- Serum magnesium level of 9.2 mg/dL (therapeutic range is 4-7 mg/dL)\n\nLet me evaluate each option:\n\nA. IV calcium gluconate 1 gram over 10 minutes\nCalcium is the specific antidote for magnesium toxicity. Calcium directly antagonizes the effects of magnesium at the neuromuscular junction and cardiac tissue. This is the standard treatment for symptomatic magnesium toxicity.\n\nB. IV furosemide 40 mg\nWhile furosemide can enhance renal excretion of magnesium, this is not the immediate treatment for acute toxicity with respiratory depression. It works too slowly for this emergency.\n\nC. Immediate hemodialysis\nHemodialysis can remove magnesium but is reserved for severe cases with renal failure. It's not the first-line immediate treatment and takes time to initiate.\n\nD. Discontinuation of magnesium and IV levothyroxine\nDiscontinuing magnesium is appropriate, but levothyroxine has no role in treating magnesium toxicity. This is incorrect.\n\nE. IV pyridostigmine\nPyridostigmine is an acetylcholinesterase inhibitor used for myasthenia gravis. It does not specifically treat magnesium toxicity.\n\nThe most specific immediate treatment for magnesium toxicity is IV calcium gluconate, which directly antagonizes magnesium's effects at the cellular level. This is the standard of care and should be given immediately after securing the airway in a patient with respiratory depression from magnesium toxicity.\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-007", "question": "A 62-year-old man with a history of asbestos exposure 30 years ago presents with unilateral right-sided pleural effusion. Thoracentesis reveals exudative fluid (by Light's criteria) with cytology positive for adenocarcinoma. PET-CT shows FDG-avid right pleural thickening and effusion, with no other distant metastases. The next best step in management is:", "options": ["Systemic chemotherapy with platinum-pemetrexed", "Pleurodesis followed by systemic chemotherapy", "Extrapleural pneumonectomy", "Pleurectomy/decortication followed by adjuvant chemoradiation", "Immunotherapy with pembrolizumab as first-line treatment"], "answer": "D", "answer_index": 3, "explanation": "This describes a likely diagnosis of malignant pleural mesothelioma (given asbestos exposure, unilateral effusion, pleural thickening). For resectable disease (stage I-III) in a fit patient, the standard of care is maximal cytoreductive surgery (pleurectomy/decortication) followed by adjuvant chemotherapy and possibly radiation. Extrapleural pneumonectomy (C) is a more radical, less commonly performed option. Systemic therapy alone (A) is for unresectable disease. Pleurodesis (B) is palliative.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "Let me analyze this case systematically.\n\nKey findings:\n- 62-year-old man with asbestos exposure 30 years ago\n- Unilateral right-sided pleural effusion\n- Exudative effusion with adenocarcinoma on cytology\n- PET-CT: FDG-avid right pleural thickening, no distant metastases\n\nDifferential diagnosis:\nThe history of asbestos exposure and pleural involvement raises concern for malignant pleural mesothelioma. However, the cytology shows adenocarcinoma, which could be:\n1. Epithelioid mesothelioma (can appear as adenocarcinoma)\n2. Metastatic adenocarcinoma to pleura (lung primary most common)\n3. Primary pleural adenocarcinoma\n\nImportant consideration:\nThe cytology shows \"adenocarcinoma\" - this is more consistent with either lung adenocarcinoma with pleural metastasis or mesothelioma. Given the asbestos history and pleural-based disease pattern, mesothelioma is highly suspected.\n\nStaging:\n- Localized to right pleura with effusion\n- No distant metastases\n- This would be potentially resectable disease\n\nTreatment options analysis:\n\nFor malignant pleural mesothelioma with localized disease:\n- Option A (Platinum-pemetrexed): Standard systemic therapy for mesothelioma, but typically for unresectable disease\n- Option B (Pleurodesis + chemo): Palliative approach\n- Option C (Extrapleural pneumonectomy): Aggressive surgery, but has fallen out of favor due to high morbidity/mortality\n- Option D (Pleurectomy/decortication + adjuvant chemoradiation): Current preferred surgical approach for resectable mesothelioma, lung-sparing with multimodal therapy\n- Option E (Pembrolizumab): Immunotherapy is now approved for mesothelioma (nivolumab + ipilimumab), but pembrolizumab alone is not standard first-line\n\nFor potentially resectable mesothelioma, the current approach favors pleurectomy/decortication (lung-sparing surgery) over extrapleural pneumonectomy, followed by adjuvant therapy. This provides local control while preserving lung function.\n\nThe answer is (D)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-008", "question": "A 40-year-old woman presents with palpitations, heat intolerance, and weight loss. TSH is <0.01 mIU/L, free T4 is 3.2 ng/dL (high). Thyroid ultrasound shows a 2 cm hypoechoic nodule in the right lobe. Radioactive iodine uptake scan shows diffusely increased uptake (45% at 24 hours) with a photopenic area corresponding to the nodule. The most likely diagnosis is:", "options": ["Graves' disease with a coexisting cold nodule", "Toxic multinodular goiter", "Subacute thyroiditis", "Factitious thyrotoxicosis", "Marine-Lenhart syndrome (Graves' disease with a functioning nodule)"], "answer": "A", "answer_index": 0, "explanation": "The diffusely increased uptake is diagnostic of Graves' disease. The photopenic ('cold') nodule within an area of diffusely high uptake indicates a non-functioning nodule, which raises concern for malignancy and requires FNA biopsy. Marine-Lenhart syndrome (E) is Graves' with a *functioning* (hot) nodule. Toxic MNG (B) would show multiple areas of increased uptake. Subacute thyroiditis (C) shows very low uptake.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nClinical Presentation:\n- 40-year-old woman with hyperthyroid symptoms (palpitations, heat intolerance, weight loss)\n- TSH <0.01 mIU/L (suppressed)\n- Free T4 3.2 ng/dL (elevated)\n- This confirms hyperthyroidism\n\nKey Imaging Findings:\n- Thyroid ultrasound: 2 cm hypoechoic nodule in right lobe\n- RAI uptake scan: \n  - Diffusely increased uptake (45% at 24 hours) - this is elevated (normal ~10-30%)\n  - Photopenic (cold) area corresponding to the nodule\n\nAnalysis of Options:\n\nA. Graves' disease with a coexisting cold nodule:\n- Graves' disease shows diffusely increased uptake due to TSH receptor antibodies stimulating the entire gland\n- A cold nodule would appear as a photopenic area within the diffusely hot gland\n- This matches the findings perfectly\n\nB. Toxic multinodular goiter:\n- Would show multiple hot and cold nodules with heterogeneous uptake\n- Not diffusely increased uptake\n- Doesn't match\n\nC. Subacute thyroiditis:\n- Would show LOW or absent RAI uptake due to thyroid inflammation\n- Doesn't match (uptake is 45%)\n\nD. Factitious thyrotoxicosis:\n- Would show LOW RAI uptake (exogenous thyroid hormone suppresses thyroid function)\n- Doesn't match\n\nE. Marine-Lenhart syndrome:\n- This is Graves' disease with a FUNCTIONING (hot) nodule\n- The nodule would show increased uptake, not be photopenic\n- Doesn't match - the nodule here is cold/photopenic\n\nThe diffusely increased uptake indicates Graves' disease (autoimmune stimulation of the entire thyroid). The photopenic/cold nodule is a separate finding - a non-functioning nodule that doesn't take up iodine. Cold nodules in Graves' disease require evaluation as they have malignancy risk.\n\nThe answer is (A)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-009", "question": "A 50-year-old man with diabetes mellitus and hypertension is found to have a serum potassium of 6.8 mEq/L on routine labs. He is asymptomatic. ECG shows peaked T waves. He is given IV calcium gluconate, insulin/dextrose, and albuterol. His potassium decreases to 6.0 mEq/L. Renal function is normal. Further workup reveals a low serum aldosterone and elevated plasma renin activity. The most likely cause of his hyperkalemia is:", "options": ["Type 4 renal tubular acidosis (hyporeninemic hypoaldosteronism)", "Addison's disease", "Gordon's syndrome (pseudohypoaldosteronism type II)", "Spironolactone use", "Rhabdomyolysis"], "answer": "C", "answer_index": 2, "explanation": "Gordon's syndrome (familial hyperkalemic hypertension) is characterized by hyperkalemia, hypertension, normal GFR, metabolic acidosis, and *suppressed* renin but *normal or high* aldosterone. The key here is the elevated renin, which rules out hyporeninemic hypoaldosteronism (A, which has low renin and low aldosterone) and points to a primary renal defect in potassium excretion. Addison's (B) has low aldosterone and high renin but also has hyponatremia and hypotension.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "Let me analyze this case systematically.\n\nKey findings:\n- 50-year-old man with diabetes mellitus and hypertension\n- Hyperkalemia (6.8 mEq/L)\n- ECG: peaked T waves\n- Normal renal function\n- Low serum aldosterone\n- Elevated plasma renin activity\n\nAnalysis of options:\n\nA. Type 4 RTA (hyporeninemic hypoaldosteronism):\n- This is common in diabetics\n- However, it presents with LOW renin AND low aldosterone\n- This patient has HIGH renin, so this doesn't fit\n\nB. Addison's disease (primary adrenal insufficiency):\n- Causes low aldosterone due to adrenal gland destruction\n- The low aldosterone leads to compensatory HIGH renin (trying to stimulate aldosterone production)\n- This matches: LOW aldosterone + HIGH renin\n- Would cause hyperkalemia and hyponatremia\n\nC. Gordon's syndrome (pseudohypoaldosteronism type II):\n- Causes hypertension and hyperkalemia\n- Characterized by LOW renin and normal/high aldosterone\n- Doesn't match the lab findings\n\nD. Spironolactone use:\n- Aldosterone receptor antagonist\n- Would cause elevated aldosterone (compensatory) and elevated renin\n- Doesn't match (aldosterone would be high, not low)\n\nE. Rhabdomyolysis:\n- Would cause hyperkalemia from muscle breakdown\n- Wouldn't specifically cause low aldosterone with high renin\n- Would expect elevated CK, myoglobinuria\n\nThe combination of LOW aldosterone with HIGH renin indicates primary adrenal insufficiency (Addison's disease). The adrenal glands cannot produce aldosterone despite elevated renin trying to stimulate production through the RAAS system.\n\nThe answer is (B)"}, {"quiz_id": "20251205T082731900Z_deepseek-v3.2_seed123", "question_id": "20251205T082731900Z_deepseek-v3.2_seed123-010", "question": "A 65-year-old man with a mechanical aortic valve (On-X) on warfarin presents with a transient ischemic attack. INR on presentation is 1.8 (target 2.5-3.5). He has no bleeding history. The most appropriate adjustment to his antithrombotic regimen is:", "options": ["Increase warfarin dose to achieve INR 2.5-3.5; add aspirin 81 mg daily", "Increase warfarin dose to achieve INR 2.5-3.5; no aspirin needed", "Switch to apixaban 5 mg twice daily", "Add clopidogrel 75 mg daily to current warfarin therapy", "Discontinue warfarin and initiate dual antiplatelet therapy with aspirin and clopidogrel"], "answer": "A", "answer_index": 0, "explanation": "For a mechanical aortic valve, the standard of care is warfarin with a target INR of 2.5-3.5. In patients who have a thromboembolic event despite therapeutic INR, adding aspirin 75-100 mg is recommended. Since his INR was subtherapeutic at the time of the TIA, the first step is to optimize INR control. However, given the event, adding low-dose aspirin is now indicated based on PROACT and other trials. Direct oral anticoagulants (C) are contraindicated in mechanical valves. Dual antiplatelet therapy (E) is inferior to warfarin for valve protection.", "generator_model": "deepseek-v3.2", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "Let me analyze this case systematically.\n\nPatient Profile:\n- 65-year-old man with mechanical aortic valve (On-X)\n- Currently on warfarin\n- Presented with TIA (transient ischemic attack)\n- Current INR: 1.8 (subtherapeutic; target is 2.5-3.5)\n- No bleeding history\n\nKey Considerations:\n\n1. Mechanical valve anticoagulation: Patients with mechanical heart valves require lifelong anticoagulation with warfarin. DOACs (like apixaban) are contraindicated in mechanical valves based on the RE-ALIGN trial, which showed increased thromboembolic and bleeding events with dabigatran.\n\n2. Subtherapeutic INR: The patient's INR of 1.8 is below the target range of 2.5-3.5, which likely contributed to the TIA. The warfarin dose needs to be increased to achieve therapeutic INR.\n\n3. Addition of aspirin: Current guidelines (ACC/AHA) recommend adding low-dose aspirin (75-100 mg daily) to warfarin therapy in patients with mechanical heart valves, particularly after a thromboembolic event. This combination has been shown to reduce thromboembolic events, though with a slight increase in bleeding risk.\n\n4. Why not other options:\n   - Option B: While increasing warfarin is correct, guidelines support adding aspirin, especially after a thromboembolic event\n   - Option C: DOACs are contraindicated with mechanical valves\n   - Option D: Clopidogrel is not the standard antiplatelet added to warfarin for mechanical valves\n   - Option E: Dual antiplatelet therapy alone is insufficient for mechanical valve thromboprophylaxis\n\nBest Answer: Increase warfarin to achieve target INR AND add low-dose aspirin 81 mg daily.\n\nThe answer is (A)"}]